Journals Journal of Oncology Pharmacy P...

Journal of Oncology Pharmacy Practice
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
OBJECTIVE: Previous cancer studies have indicated that medical marijuana addresses a significant unmet need, namely chronic pain treatment and conferring oncology supportive care. However, the clinical research evaluating medical marijuana is preliminary and requires further consideration. DATA SOURCES: We conducted a PubMed search primarily comprising retrospective and prospective studies, systematic reviews, and randomized clinical trials (RCTs) from approximately 2020-2023...
June 20, 2024: Journal of Oncology Pharmacy Practice
Hanna Yakubi, Aaron Paul Steele, Megan Tsao
INTRODUCTION: Infusion reactions, characterized by symptoms such as rigors, fever, and hypotension, are common adverse events that occur during monoclonal antibody (MAB) therapy. The treatment of rigors often involves opioids, most commonly meperidine, despite limited evidence supporting use in the setting of MAB infusions. This study aims to compare the efficacy and safety of intravenous (IV) meperidine and morphine is treatment of MAB-related rigors, filling a significant gap in the literature...
June 17, 2024: Journal of Oncology Pharmacy Practice
Safa Can Efil, Burak Bilgin, Furkan Ceylan, Hilal Karakaş, İrfan Karahan, Sema Nur Özsan, Hakan Kosku, Şebnem Yaman, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın, Mehmet Ali Nahit Şendur
OBJECTIVE: The objective of this article is to review the efficacy, safety, and evidence for current use and potential future uses of immune-checkpoint inhibitors (ICIs) in the management of resectable non-small cell lung cancer (NSCLC). DATA SOURCES: A literature review was carried out through PubMed to identify completed and ongoing clinical trials evaluating the use, efficacy, and safety of ICIs in the management of resectable NSCLC. DATA SUMMARY: To date, four phase 3 trials have emerged that have changed our treatment practice concerning the utilization of ICIs during the adjuvant and neoadjuvant settings...
June 11, 2024: Journal of Oncology Pharmacy Practice
Yulistiani Yulistiani, Erfan Abdissalam, Abdul Rahem, Nur Fauzi Hamidi, Febriansyah Nur Utomo
BACKGROUND: Cancer is among the leading causes of death globally, posing a significant economic burden on the healthcare sector. Among other types of cancer in Indonesia, non-Hodgkin lymphoma (NHL) ranks fifth in terms of prevalence. Chemotherapy for NHL patients is funded by a national health insurance scheme through the National Healthcare Insurance and Social Security/Jaminan Kesehatan Nasional (JKN). OBJECTIVE: This study aimed to analyze cost burden of chemotherapy for JKN patients with NHL...
June 11, 2024: Journal of Oncology Pharmacy Practice
Rebecca Whiting, Jeanie Misko, Matthew McGuire, Emma Fox
INTRODUCTION: Rituximab is a chimeric monoclonal antibody used to treat a range of malignant and benign haematological conditions. To minimise the risk of infusion-related toxicity, initial infusions are administered slowly over 4-6 h. In the absence of significant reactions, subsequent doses are often administered over an off-label rate of 90 min. In response to emergent data, our site adopted the use of rapid 60-min infusions for third and subsequent doses. This study aimed to review the safety and ongoing feasibility of 60-min rituximab infusions following institutional practice change...
June 7, 2024: Journal of Oncology Pharmacy Practice
Fiona Angus, Yubo Wang, Alexander Rigg, Li-Chia Chen
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have been used as the first-line treatment for many patients with renal cell carcinoma (RCC), the seventh most common cancer in the United Kingdom. However, suboptimal adherence to TKIs can result in poor clinical prognosis. This study quantified RCC patients' adherence to TKIs and explored factors associated with suboptimal adherence. METHOD: This retrospective cohort study was conducted at a specialist oncology tertiary hospital in Northwest England, using pharmacy dispensing records between November 2021 and March 2022...
June 5, 2024: Journal of Oncology Pharmacy Practice
Netty Cracknell, Catherine Parbutt, Clayton Wong, Tasneem Ganijee
INTRODUCTION: The British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) course has run for over 20 years. The ITO course is provided free of charge to BOPA PAID members, and there was an increase in cost moving to a two-day event in 2023. The BOPA Education and Training (E&T) subcommittee and BOPA Executive Committee wanted to validate that the course was meeting its objective of improving the baseline knowledge of the pharmacists and pharmacy technicians attending, and therefore justifying the increased cost to BOPA and employing organisations...
June 5, 2024: Journal of Oncology Pharmacy Practice
Mats Leeman, Maria Wetterling, Monica Kåredal, Maria Hedmer
INTRODUCTION: Antineoplastic drugs (ADs) are frequently used pharmaceuticals in the healthcare, and healthcare workers can be occupationally exposed to ADs. Monitoring of surface contamination is a common way to assess occupational exposure to ADs. The objective was to develop and validate a sensitive and quantitative monitoring method to determine surface contaminations of Pt as a marker for Pt-containing ADs. The surface contaminations of Pt-containing ADs were monitored at four Swedish hospital workplaces...
June 5, 2024: Journal of Oncology Pharmacy Practice
Faith Jelagat Magut, Amsalu Degu
INTRODUCTION: Several studies reported that drug therapy problems (DTPs) were prevalent in cancer patients. These DTPs are still interfering with the desired treatment outcomes in patients with cancer. This study aimed to determine the prevalence, types and predictors of DTPs among paediatric acute lymphoblastic leukaemia (ALL) patients at Kenyatta National Hospital. METHODS: A retrospective cohort study was used to assess DTPs among ALL patients. Records of all eligible paediatric patients with ALL who received treatment in the facility between 1 January 2017 and 31 December 2021 were examined...
June 3, 2024: Journal of Oncology Pharmacy Practice
Jennifer L Lee, Caroline F Morrison, Sarah Drake, Ahna L Pai
BACKGROUND: The purpose of this study was to describe taking, timing, and dosing adherence to home caregiver-administered intravenous (IV) immunosuppressants in a sample of pediatric hematopoietic stem cell transplant (HCT) recipients. PROCEDURES: Sixteen children who had undergone HCT, ages 3 months to 15 years, and their caregivers participated. All caregivers were biological mothers. Caregivers completed a demographic questionnaire as part of a larger study and brought in portable infusion pumps to download the pump data at the time of their child's post-HCT clinic visit...
May 31, 2024: Journal of Oncology Pharmacy Practice
Farzad Teymouri, Constantin A Dasanu
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are linked with various cutaneous side effects ranging from mild to life-threatening. Herein, we present a unique case of palmar-plantar erythrodysesthesia (PPE) in a patient treated with atezolizumab. CASE REPORT: A 72-year-old white man was diagnosed with Tumor, node, metastasis (TNM) stage IIIA lung adenocarcinoma in November 2022. He underwent right lower lobectomy and mediastinal lymphadenectomy followed by adjuvant cisplatin-pemetrexed...
May 30, 2024: Journal of Oncology Pharmacy Practice
Anisa Kamel, Melissa Sanders, Hannah Dyk, Tatum Hamilton
PURPOSE: This study aimed to characterize rasburicase dosing and duration. Secondary objectives included characterizing the indication of rasburicase and identifying the utilization of prophylactic therapy for tumor lysis syndrome (TLS). METHODS: This retrospective review included patients 0 to 89 years old admitted between 1 January 2021 and 31 December 2021, and received at least one dose of rasburicase. Patients were excluded if they were >89 years old, pregnant, lactating, or received rasburicase outpatient...
May 25, 2024: Journal of Oncology Pharmacy Practice
Ann-Louise Slee, John Coutsouvelis, Bianca Tong, Susan Poole, John Zalcberg
BACKGROUND: Pembrolizumab, an immune checkpoint inhibitor, indicated to treat multiple cancers, was initially approved in Australia as weight-based dosing at 2 mg/kg every 3 weeks (Q3W). Subsequent approvals used 'fixed' dosages of 200 mg Q3W or 400 mg every 6 weeks (Q6W). Pharmacokinetic equivalence was demonstrated between dosing strategies, with no significant differences in efficacy or toxicity. Fixed dosing regimens are routinely used in Australia. AIM: To model and compare the cost of weight-based dosing of pembrolizumab to standard fixed dosing regimens...
May 23, 2024: Journal of Oncology Pharmacy Practice
Arzu Babacan
OBJECTIVE: Oxaliplatin is a platinum-group chemotherapeutic agent commonly used in the treatment of colorectal cancer. In addition to hematological and gastrointestinal side effects, laryngopharyngeal dysesthesia associated with cold is reported as a rare side effect. In this article, seven cases with pharyngolaryngeal dysesthesia were presented and the diagnosis and treatment planning were reviewed in the light of literature findings. MATERIAL AND METHODS: Patient records of cancer patients with laryngopharyngeal dysesthesia were retrospectively analyzed between 2020 and 2023...
May 22, 2024: Journal of Oncology Pharmacy Practice
Cheyanne Shook, John Malamakal, Michael J Gass, Audrey Brown, Christopher R Frei, Amy Horowitz
As cancer treatments shift from traditional intravenous chemotherapy to inclusion of oral oncolytics, there is a critical need for structured oral chemotherapy monitoring and follow-up programs. To provide continuous care and minimize clinical gaps to Veterans receiving oral chemotherapy, the hematology/oncology clinical pharmacy practitioners designed and initiated a pilot, pharmacist-driven, Oral Chemotherapy Monitoring Clinic at the South Texas Veterans Health Care System supported by an oral chemotherapy certified pharmacy technician...
May 21, 2024: Journal of Oncology Pharmacy Practice
Zengqing Ma, Jianguo Zhao, Susu Li, Fuping Gao, Chuanyang Zhang, Lianping Wu, Yu Lin
INTRODUCTION: Imatinib, a tyrosine kinase inhibitor, is the first-line therapy for patients with KIT mutation in gastrointestinal stromal tumor (GIST). Nausea, vomiting, diarrhea, dyspepsia and abdominal pain are common gastrointestinal adverse reactions of imatinib, but imatinib-induced ulcerative colitis (UC) is rarely reported. CASE REPORT: We presented a case of UC induced by imatinib in a 56-year-old male patient who experienced this adverse event after 5 years of imatinib 400 mg/d treatment following GIST resection...
May 21, 2024: Journal of Oncology Pharmacy Practice
Hawaryaw Mathewos Hadero, Melak Gedamu Beyene, Assefa Mulu Baye, Eskinder Ayalew Sisay
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is a major issue for chemotherapy pediatric patients, especially in developing countries due to limited access to essential antiemetics. This study aimed to assess antiemetic prophylaxis outcomes in pediatric cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia. METHODS: A longitudinal prospective observational study design was conducted among 201 pediatric cancer patients followed up to 120 h post-chemotherapy...
May 21, 2024: Journal of Oncology Pharmacy Practice
Ariana Maia, Daniela M Soares, Sofia Azevedo, Teresa Pereira, Cláudia Amaral
INTRODUCTION: Immunotherapy has a crucial role in the current treatment of multiple malignancies. Albeit described as rare, new onset autoimmune diabetes is a potentially life-threatening complication of programmed cell death-1 (PD-1) inhibitors, such as pembrolizumab, and its predisposing factors and pathological mechanism are yet to be clarified. CASE REPORT: We present a case of a 72-year-old man with a high-grade bladder carcinoma undergoing pembrolizumab treatment...
May 20, 2024: Journal of Oncology Pharmacy Practice
Aslınur Albayrak, Bahar Erbay, Erkan Kayıkçıoğlu
INTRODUCTION: This study aimed to determine polypharmacy, potentially inappropriate medications, and potential drug-drug interactions in elderly patients hospitalized in the oncology services of a university hospital in Turkey. METHODS: This retrospective cross-sectional study was conducted between September 2021 and September 2022 on cancer patients over 65 years old hospitalized at Suleyman Demirel University Medical Faculty Hospital in Isparta, Turkey. Potentially inappropriate medications were defined according to the 2023 Beers Criteria of the American Geriatrics Society...
May 16, 2024: Journal of Oncology Pharmacy Practice
Nathalie Nguyen, Virginie Vallet, Lucie Bouchoud, Ludivine Falaschi, Serge Rudaz, Pascal Bonnabry, Sandrine Fleury-Souverain
INTRODUCTION: Due to the high toxicity of antineoplastic drugs, handling their packaging could lead to the chemical contamination of hospital environments and exposure risks to healthcare professionals and patients. This study aimed to assess the contamination of two main surfaces: the outer primary packaging of oral antineoplastic drug formulations ( n   =  36) available on the Swiss market and the surface of secondary packaging of injectable antineoplastic drug preparations ( n   =  60) produced by the pharmacy of a Swiss hospital and carriers used for transport ( n   =  5)...
May 15, 2024: Journal of Oncology Pharmacy Practice
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.